Correspondence to 'Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression'

We read with great interest the work by Watad *et al.*¹ which the authors demonstrated the characterisation of enthesis-resident T cells and their corresponding cytokine responses upon stimulation. This commendable work mimicked enthesitis-involved inflammatory pathogenesis of spondyloarthritis, for instance, psoriatic arthritis (PsA). Particularly, the authors proposed that enthesal T cells may secrete interleukin (IL)-17 and much more tumour necrosis factor α (TNF- α) in response to anti-CD3 and anti-CD28 (as suggested in figure 3 by Watad *et al.*¹); furthermore, phosphodiesterase 4 (PDE4) inhibitors suppressed the expression of the above mentioned inflammatory cytokines (as suggested in figure 5 by Watad *et al.*¹). As PDE4 inhibitors have been used to treat autoimmune diseases and advanced malignancies,² we are highly interested in whether infliximab, a neutralised antibody for TNF- α and a widely prescribed biologic disease-modifying antirheumatic drugs for a number of autoimmune diseases, would as well modulate the immunity of enthesal or synovial T cells in patients with PsA in clinical settings.

We compared the RNA-sequencing profiles of synovial biopsies from patients with PsA naive to anti-TNF- α agents before and 10 weeks after infliximab treatment registered in the National Center for Biotechnology Information-Gene Expression Omnibus database. Overall, we identified 39 significantly expressed pathways using p value and Z-score visualisation, with 26 pathways up-regulated at a Z-score of above 1, and 13 pathways down-regulated at a Z-score of less than -1 (figure 1). Among the 26 upregulated pathways after infliximab treatment, well-documented immunomodulatory signalling pathways, including adrenomedullin signalling pathway,³ transforming growth factor- β (TGF- β) signalling and aryl

hydrocarbon receptor signalling, were noted; furthermore, B cell-involved pathways, including B cell receptor signalling and systemic lupus erythematosus-associated B cell signalling pathway, were as well activated after TNF- α blockage. Among the 13 downregulated pathways after infliximab treatment, both Tec kinase signalling and signalling by Rho family GTPases were significantly inhibited at a Z-score of less than -2. These findings are consistent with previous studies reporting that Tec kinases regulate signalling pathways downstream of T cell receptor (TCR) activation, followed by T cell development, cytokine production and T-helper cell differentiation.⁴ On the other hand, these findings are in line with the fact that Rho GTPases initiate signalling following TCR activation, which allow them to modulate pathways responsible for T cell development, differentiation and activation.⁵ Moreover, as IL-23 signalling, a pathway upstream of Th17 induction,⁶ was also downregulated after infliximab treatment, it was suggested that reciprocal regulation between TNF- α and IL-17 took place in synovial T cells during anti-TNF- α therapy.⁷

In conclusion, our data supported that the activity of enthesal and synovial T cells was suppressed in patients with PsA treated with TNF- α inhibitors, potentially accompanying with an overall downregulation in pathways underlying the pathogenesis of PsA.

Li-Tzu Wang,¹ Kevin Sheng-Kai Ma²

¹Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan, Republic of China

²Department of Life Science, National Taiwan University, Taipei, Taiwan, Republic of China

Correspondence to Dr Kevin Sheng-Kai Ma, National Taiwan University, Taipei, Republic of China; sheng.kai.ma@cern.ch

Contributors Both authors contributed equally to conceptualization, data analysis and discussion.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

L-TW and KS-KM are joint first authors.

To cite Wang L-T, Ma KS-K. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218995

Received 31 August 2020

Accepted 3 September 2020

► <http://dx.doi.org/10.1136/annrheumdis-2020-219047>

Ann Rheum Dis 2020;0:1–2. doi:10.1136/annrheumdis-2020-218995

ORCID iD

Kevin Sheng-Kai Ma <http://orcid.org/0000-0002-9394-4144>

REFERENCES

- 1 Watad A, Rowe H, Russell T, *et al.* Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. *Ann Rheum Dis* 2020;79:1044–54.

Figure 1 Canonical pathway analysis on RNA-seq data of synovial biopsy from patients with psoriatic arthritis receiving infliximab treatment after a follow-up of 10 weeks. Upregulated pathways are labelled in red. Downregulated pathways are labelled in blue. FGF, fibroblast growth factor; FLT3, FMS-like tyrosine kinase 3; GNRH, gonadotropin-releasing hormone; IL, interleukin; ILK, integrin-linked kinase; LXR, liver X receptor; NANOG, homeobox transcription factor Nanog; PFKFB4, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4; PPAR α , peroxisome proliferator-activated receptor α ; RXR, retinoid X receptor; TRK, tropomyosin receptor kinase; VEGF, vascular endothelial growth factor.

- 2 Kelly K, Mejia A, Suhasini AN, *et al.* Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B-cell malignancies. *Clin Cancer Res* 2017;23:1186–92.
- 3 Matson BC, Caron KM. Adrenomedullin and endocrine control of immune cells during pregnancy. *Cell Mol Immunol* 2014;11:456–9.
- 4 Lucas JA, Miller AT, Atherly LO, *et al.* The role of Tec family kinases in T cell development and function. *Immunol Rev* 2003;191:119–38.
- 5 Saoudi A, Kassem S, Dejean A, *et al.* Rho-GTPases as key regulators of T lymphocyte biology. *Small GTPases* 2014;5. doi:10.4161/sgtp.28208. [Epub ahead of print: 08 May 2014].
- 6 Gaffen SL, Jain R, Garg AV, *et al.* The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. *Nat Rev Immunol* 2014;14:585–600.
- 7 Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *J Allergy Clin Immunol* 2017;140:645–53.